Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells

23 Aug 2023

Abstract excerpt

BACKGROUND: As the COVID-19 pandemic continues to evolve, novel vaccines need to be developed that are readily manufacturable and provide clinical efficacy against emerging SARS-CoV-2 variants. Virus-like particles (VLPs) presenting the spike antigen at their surface offer remarkable benefits over other vaccine antigen formats; however, current SARS-CoV-2 VLP vaccines candidates in clinical development suffer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Transgenic Plants and Applications
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37612423
DOI: 10.1038/s43856-023-00340-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cellsPMID 37612423Read ↗

A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2Semantic proximity Read ↗

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell PoolSemantic proximity Read ↗

A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigensSemantic proximity Read ↗

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particlesSemantic proximity Read ↗

Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cellsSemantic proximity Read ↗

SARS-CoV-2 protein ORF8 limits expression levels of Spike antigen and facilitates immune evasion of infected host cellsSemantic proximity Read ↗

Recombinant SARS-CoV-2 spike proteins for sero-surveillance and epitope mappingSemantic proximity Read ↗

SARS-CoV-2 Virus like Particles produced by a single recombinant baculovirus generate potent neutralizing antibody that protects against variant challengeSemantic proximity Read ↗

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccinesSemantic proximity Read ↗

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.Semantic proximity Read ↗

A method for the generation of pseudotyped virus particles bearing SARS coronavirus spike protein in high yieldsSemantic proximity Read ↗

SARS CoV-2 nucleoprotein enhances the infectivity of lentiviral spike particlesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.